"Revlimid" A Step Closer To Being Approved For New Cases Of Multiple Myeloma

Celgene Corp's cancer drug Revlimid met its main goal in the drug's phase III late-stage trial, meaning that the medication is one step closer to being approved for new cases of multiple myeloma.

http://www.medicalnewstoday.com/articles/263282.php